Edison Investment Research - Zamanco Minerals (ZAM) Update: Margins under pressure

Report

Edison Investment Research

Update: Margins under pressure

Zambeef continues to make progress towards becoming one of the leading food producers across sub-Saharan Africa rather than solely Zambia. This progress is currently overshadowed by several adverse external effects, which have resulted in Zambeef posting a $3.2m adjusted pre-tax loss in H114. Our revised estimates look for a return to profitability in FY15. We revise our valuation range from 26-41p to 16-36p.

26/06/2014 8 EN

Underlying

Zamanco Minerals

Zamanco Minerals Limited is an Australia-based company, which continues to seek a transaction of merit capable of becoming the primary undertaking of the Company. The Company focuses on identifying and evaluating a business opportunity. It has undertaken evaluation of a range of prospects in various industries.

See profile

AU000000ZAM5 Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Edison Investment Research

Update: Growth in cold chain business drives turnaround

During H115, Zambeef has made significant progress in improving the profitability of its core cold chain food distribution businesses. Gross profits from the beef, chicken, pork, milk, eggs and fish operations rose by 29% year on year to $21.3m (48% in kwacha terms), resulting in the group generating $0.1m profit before tax (adjusted for unrealised forex) compared with a $3.2m loss in H114. Following the disposal of the non-core Zamanita business which completed earlier this month, we reinstate our estimates and see fair value at 17-30p.

June 23, 2015 June 23, 2015 7 EN

Edison Investment Research

Update: Termination of coverage

Edison Investment Research is terminating coverage on Zambeef Products (ZAM). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

June 22, 2015 June 22, 2015 1 EN

Edison Investment Research

Flash note: Disposal of Zamanita completed

Zambeef has sold its Zamanita subsidiary to Cargill for US$26.4m, payable in cash. Zamanita is one of the largest edible oil and soybean meal producers in Zambia, but is no longer a core business, is capital intensive, inherently lower margin than the cold store chain activities and exposed to fluctuations in global commodity prices and foreign exchange rates. The disposal is in line with the groupâ€™s stated strategy of unlocking the value of its assets. It enables management to focus on the groupâ€™s cold store chain activities and reduces potential earnings volatility. The transaction reduc...

June 2, 2015 June 2, 2015 2 EN

IP Group - Several potential portfolio catalysts on the horizon

IP Group’s NAV declined by 13% in total return (TR) terms in FY23, affected by continued soft valuations across venture capital (VC) markets, as well as funding delays at some of its holdings. That said, management indicated that many of IP Group’s portfolio companies continued to make strong progress. Its maturing portfolio offers a number of potential NAV triggers and is now available at a wide 59% discount to NAV. We note that, as at end-2023, only 14% of IP Group’s portfolio was valued based on funding rounds completed more than 12 months ago and 46% of its private portfolio was valued by ...

1h / 49m 1h / 49m 1 EN

Sean Conroy

Sean Conroy

Actinogen Medical - First patient dosed in Phase IIb XanaMIA study

Actinogen Medical announced that the first randomised patient in its Phase IIb XanaMIA trial of lead candidate Xanamem received their first treatment on Friday 12 April. This study is designed to enrol c 220 patients with cognitive impairment (CI) associated with biomarker-positive mild-to-moderate Alzheimer’s disease (AD), as confirmed through an elevated level of phosphorylated Tau-181 (pTau-181) protein in their blood at baseline. The study has commenced at 13 Australian sites and will concentrate on domestic sites for the first c 100 patients, and initial efficacy and safety results will b...

4h / 7m 4h / 7m 1 EN

Sean Conroy

Sean Conroy

Cereno Scientific - CS014 (thrombosis) progresses towards the clinic

Cereno Scientific has taken a step closer to advancing its second asset, CS014, a novel HDAC inhibitor with epigenetic effects, to the clinic with the submission of the clinical trial application (CTA) to the European Medicines Agency (EMA). The CTA is for the first-in-human Phase I trial for CS014, which Cereno is developing for thrombosis prevention, without increased risk of bleeding. We believe this has the potential to address the main limitation of current standard-of-care antithrombotic medicines and offers a sizeable opportunity for Cereno (backed by supportive preclinical data). Subje...

4h / 29m 4h / 29m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Update: Margins under pressure

Update: Growth in cold chain business drives turnaround

Update: Termination of coverage

Flash note: Disposal of Zamanita completed

IP Group - Several potential portfolio catalysts on the horizon

Actinogen Medical - First patient dosed in Phase IIb XanaMIA study

Cereno Scientific - CS014 (thrombosis) progresses towards the clinic

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe